Last reviewed · How we verify

NCT06814327: AI4ICU-Obs

Assessment of Organ Failure Risk Predictions in ICU

Active, enrolled Last updated 28 August 2025
What this trial tests

trial in Circulatory Failure in 499 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
18 November 2024
Primary endpoint
15 May 2025
15 May 2026

Quick facts

Lead sponsorETH Zurich
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment499
Start date18 November 2024
Primary completion15 May 2025
Estimated completion15 May 2026
Sites1 location across Switzerland

Conditions studied

Sponsor

ETH Zurich — full company profile →

Who can join

18 and older, any sex, with Circulatory Failure or Respiratory Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

During this observational study, the investigators aim to assess the ability of ICU clinicians to predict the risk of impending organ failure and retrospectively compare it to the performance of previously published machine learning models. The central hypothesis of this study is that the treating physician can predict impending organ failure in adult ICU patients with similar accuracy as the best previously publishes machine learning models.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Circulatory Failure

Currently open trials in the same condition.

Other ETH Zurich trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06814327.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing